A tale of two TrkA inhibitor trials: same target, divergent results.
作者信息
Walsh D A, Neogi T
机构信息
Pain Centre Versus Arthritis, and NIHR Nottingham Biomedical Research Centre, Academic Rheumatology, University of Nottingham, UK.
Section of Rheumatology, Boston University School of Medicine, USA.
出版信息
Osteoarthritis Cartilage. 2019 Nov;27(11):1575-1577. doi: 10.1016/j.joca.2019.07.013. Epub 2019 Jul 26.
Abstract
摘要
相似文献
1
A tale of two TrkA inhibitor trials: same target, divergent results.
Osteoarthritis Cartilage. 2019 Nov;27(11):1575-1577. doi: 10.1016/j.joca.2019.07.013. Epub 2019 Jul 26.
2
Response to: 'Role of nerve growth factor (NGF) and tropomyosin receptor kinase A (TrkA) in the pathogenesis of osteoarthritis. Might NGF be the link interwinding obesity and OA?' by Iannone et al.
Ann Rheum Dis. 2015 Dec;74(12):e71. doi: 10.1136/annrheumdis-2015-208523. Epub 2015 Sep 29.
3
Osteoarthritis in 2016: Anti-NGF treatments for pain - two steps forward, one step back?
Nat Rev Rheumatol. 2017 Jan 25;13(2):76-78. doi: 10.1038/nrrheum.2016.224.
4
Role of nerve growth factor and tropomyosin receptor kinase A in the pathogenesis of osteoarthritis. Might nerve growth factor be the link interwinding obesity and osteoarthritis?
Ann Rheum Dis. 2015 Dec;74(12):e70. doi: 10.1136/annrheumdis-2015-208519. Epub 2015 Sep 18.
5
Blocking the tropomyosin receptor kinase A (TrkA) receptor inhibits pain behaviour in two rat models of osteoarthritis.
Ann Rheum Dis. 2016 Jun;75(6):1246-54. doi: 10.1136/annrheumdis-2014-207203. Epub 2015 Aug 18.
6
Tropomyosin-related kinase A (TrkA) inhibition for the treatment of painful knee osteoarthritis: results from a randomized controlled phase 2a trial.
Osteoarthritis Cartilage. 2019 Nov;27(11):1590-1598. doi: 10.1016/j.joca.2019.05.029. Epub 2019 Jul 26.
7
Efficacy and safety of intra-articular injection of tropomyosin receptor kinase A inhibitor in painful knee osteoarthritis: a randomized, double-blind and placebo-controlled study.
Osteoarthritis Cartilage. 2019 Nov;27(11):1599-1607. doi: 10.1016/j.joca.2019.05.028. Epub 2019 Jul 25.
8
[The fine line between innovation and risk : Is anti-NGF a pain medication of the future?].
Schmerz. 2010 Dec;24(6):559-60. doi: 10.1007/s00482-010-0993-0.
9
The Efficacy, Tolerability, and Joint Safety of Fasinumab in Osteoarthritis Pain: A Phase IIb/III Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
Arthritis Rheumatol. 2019 Nov;71(11):1824-1834. doi: 10.1002/art.41012. Epub 2019 Sep 20.
10
Acetaminophen in Perspective.
J Am Geriatr Soc. 2016 Nov;64(11):2397-2398. doi: 10.1111/jgs.14339. Epub 2016 Sep 14.
引用本文的文献
1
From neuromodulation to bone homeostasis: therapeutic targets of nerve growth factor in skeletal diseases.
Front Pharmacol. 2025 Aug 11;16:1614542. doi: 10.3389/fphar.2025.1614542. eCollection 2025.
2
Peripheral neuronal sensitization and neurovascular remodelling in osteoarthritis pain.
Nat Rev Rheumatol. 2025 Aug 12. doi: 10.1038/s41584-025-01280-3.
3
New developments in osteoarthritis pharmacological therapies.
Rheumatology (Oxford). 2021 Dec 24;60(Suppl 6):vi1-vi11. doi: 10.1093/rheumatology/keab679.
4
An update on targets for treating osteoarthritis pain: NGF and TRPV1.
Curr Treatm Opt Rheumatol. 2020 Sep;6(3):129-145. doi: 10.1007/s40674-020-00146-x. Epub 2020 May 6.
5
Future projections of opioid use and cost in patients with chronic osteoarthritis pain in Spain.
Ther Adv Musculoskelet Dis. 2021 Apr 29;13:1759720X211010599. doi: 10.1177/1759720X211010599. eCollection 2021.
6
Peripheral pain mechanisms in osteoarthritis.
Pain. 2020 Sep;161 Suppl 1(1):S138-S146. doi: 10.1097/j.pain.0000000000001923.
本文引用的文献
1
Peripheral brain-derived neurotrophic factor contributes to chronic osteoarthritis joint pain.
Pain. 2020 Jan;161(1):61-73. doi: 10.1097/j.pain.0000000000001694.
2
Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial.
JAMA. 2019 Jul 2;322(1):37-48. doi: 10.1001/jama.2019.8044.
3
Chronic pain after total knee arthroplasty.
EFORT Open Rev. 2018 Aug 16;3(8):461-470. doi: 10.1302/2058-5241.3.180004. eCollection 2018 Aug.
4
Traits associated with central pain augmentation in the Knee Pain In the Community (KPIC) cohort.
Pain. 2018 Jun;159(6):1035-1044. doi: 10.1097/j.pain.0000000000001183.
5
Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models?
Curr Opin Rheumatol. 2017 Jan;29(1):110-118. doi: 10.1097/BOR.0000000000000354.
6
Effectiveness and Implications of Alternative Placebo Treatments: A Systematic Review and Network Meta-analysis of Osteoarthritis Trials.
Ann Intern Med. 2015 Sep 1;163(5):365-72. doi: 10.7326/M15-0623.
7
Neuropathic pain symptoms on the modified painDETECT correlate with signs of central sensitization in knee osteoarthritis.
Osteoarthritis Cartilage. 2013 Sep;21(9):1236-42. doi: 10.1016/j.joca.2013.06.023.
8
Antagonism of nerve growth factor-TrkA signaling and the relief of pain.
Anesthesiology. 2011 Jul;115(1):189-204. doi: 10.1097/ALN.0b013e31821b1ac5.
9
The majority of myelinated and unmyelinated sensory nerve fibers that innervate bone express the tropomyosin receptor kinase A.
Neuroscience. 2011 Mar 31;178:196-207. doi: 10.1016/j.neuroscience.2011.01.039. Epub 2011 Jan 26.
10
Angiogenesis and nerve growth factor at the osteochondral junction in rheumatoid arthritis and osteoarthritis.
Rheumatology (Oxford). 2010 Oct;49(10):1852-61. doi: 10.1093/rheumatology/keq188. Epub 2010 Jun 26.
Zotero 插件